These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31997802)

  • 41. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease.
    Sullivan AM; Pohl J; Blunt SB
    Eur J Neurosci; 1998 Dec; 10(12):3681-8. PubMed ID: 9875347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined cell-based therapy strategies for the treatment of Parkinson's disease: focus on mesenchymal stromal cells.
    Rodríguez-Pallares J; García-Garrote M; Parga JA; Labandeira-García JL
    Neural Regen Res; 2023 Mar; 18(3):478-484. PubMed ID: 36018150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
    Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
    Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo.
    Gavin AM; Walsh S; Wyatt S; O'Keeffe GW; Sullivan AM
    Neurosci Lett; 2014 Feb; 561():176-81. PubMed ID: 24373993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
    Tanriover G; Seval-Celik Y; Ozsoy O; Akkoyunlu G; Savcioglu F; Hacioglu G; Demir N; Agar A
    Folia Histochem Cytobiol; 2010 Sep; 48(3):434-41. PubMed ID: 21071351
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BMP-Smad 1/5/8 signalling in the development of the nervous system.
    Hegarty SV; O'Keeffe GW; Sullivan AM
    Prog Neurobiol; 2013 Oct; 109():28-41. PubMed ID: 23891815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.
    Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M
    Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts.
    Rosenblad C; Martinez-Serrano A; Björklund A
    Neuroscience; 1996 Dec; 75(4):979-85. PubMed ID: 8938733
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
    Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electroacupuncture-regulated neurotrophic factor mRNA expression in the substantia nigra of Parkinson's disease rats.
    Wang S; Fang J; Ma J; Wang Y; Liang S; Zhou D; Sun G
    Neural Regen Res; 2013 Feb; 8(6):540-9. PubMed ID: 25206697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Naringin: a protector of the nigrostriatal dopaminergic projection.
    Jung UJ; Leem E; Kim SR
    Exp Neurobiol; 2014 Jun; 23(2):124-9. PubMed ID: 24963276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mesenchymal stem cells and neuroregeneration in Parkinson's disease.
    Glavaski-Joksimovic A; Bohn MC
    Exp Neurol; 2013 Sep; 247():25-38. PubMed ID: 23542820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson's disease models.
    Ucar B; Humpel C
    Brain Res Bull; 2019 Jul; 149():86-95. PubMed ID: 31004735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
    Rosenblad C; Martinez-Serrano A; Björklund A
    Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain-derived neurotrophic factor (BDNF) mediates bone morphogenetic protein-2 (BMP-2) effects on cultured striatal neurones.
    Gratacòs E; Checa N; Pérez-Navarro E; Alberch J
    J Neurochem; 2001 Nov; 79(4):747-55. PubMed ID: 11723167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease.
    Hoban DB; Howard L; Dowd E
    Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.